This common vaccine cuts heart risk nearly in half in new study

These compelling findings, poised to significantly influence preventative cardiology, emerged from groundbreaking research presented at the American College of Cardiology’s Annual Scientific Session (ACC.26). The study provides robust evidence that the shingles vaccine offers substantial benefits beyond its primary role in preventing herpes zoster, extending to a crucial reduction in cardiovascular morbidity and mortality, particularly within a high-risk patient population already battling atherosclerotic heart disease.

The retrospective cohort study meticulously analyzed data from over 246,822 adults across the United States, all previously diagnosed with atherosclerotic heart disease (ASCVD), a chronic condition characterized by plaque buildup in the arteries that can lead to heart attacks, strokes, and other severe cardiovascular events. The results significantly bolster a growing body of scientific literature suggesting a broader cardioprotective effect of the shingles vaccine, potentially even influencing the risk of conditions such as dementia.

Dr. Robert Nguyen, a resident physician at the University of California, Riverside, and the lead author of the study, underscored the cumulative nature of these findings. "This vaccine has been found over and over again to have cardioprotective effects for reducing heart attack, stroke and death," Dr. Nguyen stated. He further emphasized the profound implications for a vulnerable demographic: "Looking at the highest risk population, those with existing cardiovascular disease, these protective effects might be even greater than among the general public." This observation is critical, as patients with established ASCVD face a considerably elevated risk of recurrent cardiovascular events, making any intervention that can mitigate this risk exceptionally valuable.

Understanding the Interplay: Shingles, Inflammation, and Heart Health

To fully appreciate the study’s significance, it is essential to understand the underlying mechanisms linking shingles and cardiovascular disease. Shingles, or herpes zoster, is caused by the reactivation of the varicella-zoster virus (VZV), the same virus responsible for chickenpox. After a primary chickenpox infection, VZV lies dormant in nerve cells and can reactivate years or decades later, typically due to age-related decline in immunity or immunocompromised states. The reactivation manifests as a painful, blistering rash, often accompanied by debilitating nerve pain known as postherpetic neuralgia (PHN), which can persist for months or even years.

The Centers for Disease Control and Prevention (CDC) currently recommends the shingles vaccine for all adults aged 50 years and older, as well as younger individuals with weakened immune systems. This recommendation is primarily aimed at preventing the painful rash and its neurological sequelae. However, emerging research has shed light on a more insidious connection between a shingles infection and systemic inflammation, a key driver of cardiovascular disease.

When VZV reactivates, it can trigger a potent inflammatory response throughout the body. This systemic inflammation is known to contribute to endothelial dysfunction – damage to the inner lining of blood vessels – and can promote the formation of blood clots. Specifically, earlier research has demonstrated that shingles infections can precipitate blood clot formation near vital organs like the brain and heart. This inflammatory cascade and pro-thrombotic state significantly elevate the risk of acute cardiovascular events, including myocardial infarction (heart attack), ischemic stroke, and venous thromboembolism (VTE). By effectively preventing the shingles infection, the vaccine thus interrupts this dangerous inflammatory pathway, thereby reducing the likelihood of these serious clotting events and their associated cardiovascular consequences.

A Chronology of Discovery: From Shingles Prevention to Cardiovascular Protection

The understanding of the shingles vaccine’s broader benefits has evolved over time, building upon a series of scientific discoveries:

• Early 2000s: The First Generation Vaccine: The initial shingles vaccine, Zostavax (a live attenuated vaccine), was approved in 2006. Its primary objective was to prevent shingles and reduce the severity and duration of PHN. While effective, its efficacy waned over time and was not suitable for immunocompromised individuals.
• Mid-2010s: Linking Shingles Infection to CV Risk: Around this period, observational studies began to highlight a statistically significant association between an acute shingles episode and an increased risk of subsequent cardiovascular events. For instance, a landmark study published in the Journal of the American College of Cardiology in 2017 found that shingles was associated with a higher risk of heart attack and stroke, with the risk particularly pronounced in younger adults (under 40) who contracted shingles. Other studies noted increased stroke risk in the months following a shingles diagnosis. These findings spurred further investigation into the systemic effects of VZV reactivation.
• 2017: Introduction of Shingrix: The landscape of shingles prevention dramatically changed with the approval of Shingrix, a recombinant zoster vaccine, in 2017. Shingrix demonstrated significantly higher efficacy (over 90%) in preventing shingles across all age groups and provided more durable protection, making it the preferred vaccine. Its non-live composition also made it safe for immunocompromised individuals.
• Late 2010s/Early 2020s: Early Evidence of Vaccine’s CV Benefits: With the advent of a more effective vaccine, researchers began to explore whether vaccination itself could mitigate the cardiovascular risks associated with shingles. Preliminary studies started to suggest a link between shingles vaccination and a reduced incidence of cardiovascular events in the general population. A prior study, mentioned in the context of this new research (and hypothetically published in 2025 in the original article), reportedly found a 23% reduction in cardiovascular events in generally healthy adults following shingles vaccination, with benefits potentially lasting up to eight years.
• ACC.26 (March 202X): Consolidating Evidence in High-Risk Patients: Dr. Nguyen’s presentation at ACC.26 marks a critical juncture. By focusing specifically on individuals with pre-existing atherosclerotic heart disease, this study provides the strongest evidence to date for the vaccine’s cardioprotective role in a population already highly vulnerable to cardiovascular events. It bridges the gap between understanding the risk of shingles and demonstrating the benefit of vaccination in a clinically meaningful way for cardiologists and their patients.

A Large-Scale Analysis Reveals Significant Risk Reduction

To execute their comprehensive analysis, the research team leveraged TriNetX, an extensive federated research network containing de-identified electronic medical records from millions of Americans. This robust database allowed for the examination of a large and diverse patient cohort, enhancing the generalizability of the findings.

The study population comprised adults aged 50 years or older diagnosed with atherosclerotic disease, observed between 2018 and 2025. The analysis meticulously compared 123,411 individuals who had received at least one dose of either the Shingrix or Zostavax vaccine with an equally sized control group of 123,411 unvaccinated individuals. Crucially, both groups were carefully matched to ensure similarity across various demographic characteristics, including age, gender, race, ethnicity, and a wide array of other pre-existing health conditions (comorbidities) and socioeconomic factors. This matching process is vital in observational studies to minimize confounding variables and strengthen the attribution of observed outcomes to the vaccination status.

Researchers specifically focused on a range of heart-related outcomes that occurred within a defined period: between one month and one year following vaccination for the vaccinated group, and within the equivalent timeframe for the unvaccinated control group. The results were striking and consistent across all measured outcomes:

• Major Adverse Cardiac Events (MACE): Vaccinated individuals were 46% less likely to experience a MACE, a composite endpoint often including heart attack, stroke, and cardiovascular death.
• All-Cause Mortality: Perhaps the most compelling finding, vaccinated patients exhibited a remarkable 66% lower likelihood of dying from any cause during the follow-up period.
• Heart Attack (Myocardial Infarction): The risk of suffering a heart attack dropped by 32% in the vaccinated group.
• Stroke: Vaccinated individuals were 25% less likely to experience a stroke.
• Heart Failure: The risk of developing heart failure also decreased by 25%.

These percentage reductions are not merely statistically significant; they represent clinically meaningful improvements in patient outcomes. Dr. Nguyen emphasized the magnitude of these benefits, noting that they are "substantial and comparable to the benefits seen from quitting smoking." This powerful analogy underscores the significant impact that shingles vaccination could have on cardiovascular health, elevating its status from a preventative measure for a painful rash to a vital component of comprehensive cardiovascular risk reduction strategies. The findings, Dr. Nguyen concluded, powerfully reinforce the existing CDC recommendations for adults over age 50 to receive the vaccine.

Broader Implications for Public Health and Clinical Practice

The implications of this research are far-reaching, touching upon public health policy, clinical guidelines, and patient education.

Reinforcing Current Recommendations: While the CDC already advises shingles vaccination for adults 50 and older, these findings provide a new and compelling layer of justification. For clinicians, especially cardiologists, discussing shingles vaccination with their ASCVD patients can now be framed not just as a way to avoid a painful rash, but as a direct intervention to protect their heart.

Addressing Vaccine Hesitancy: In an era grappling with vaccine misinformation and hesitancy, studies like this offer critical evidence-based counterpoints. Dr. Nguyen highlighted this point directly: "Vaccines are one of the most important medicines we have to prevent disease. Sometimes patients are unsure about whether they should get a vaccine or not, particularly in an age of disinformation. These results provide another reason for them to elect to get the vaccine." This research equips healthcare providers with an additional, powerful argument to encourage vaccination, potentially improving uptake rates among a demographic that stands to benefit immensely.

Integrated Care and Preventative Cardiology: The study reinforces the concept of integrated care, where preventative measures for one condition (shingles) yield significant benefits for another major health concern (cardiovascular disease). It encourages a holistic approach to patient management, prompting cardiologists to consider immunization status as part of a comprehensive risk assessment. The American College of Cardiology, a leading professional organization, is likely to carefully review these findings, potentially influencing future clinical guidelines that could advocate more strongly for shingles vaccination in high-risk cardiovascular patients. This aligns with the ACC’s mission to transform cardiovascular care and improve heart health through evidence-based practices.

Economic Impact: While not explicitly detailed in the study, a reduction in major adverse cardiac events, heart attacks, strokes, and all-cause mortality would inevitably translate into substantial healthcare cost savings. Preventing these severe events avoids costly hospitalizations, complex medical procedures, long-term rehabilitation, and lost productivity, making the shingles vaccine a potentially cost-effective public health intervention from an economic perspective as well.

Limitations and Future Research Directions

Despite the robust nature of this large-scale study, it is important to acknowledge certain limitations inherent to observational research.

Observational Nature and Confounding Factors: As a retrospective observational study, it can demonstrate association rather than direct causation. While researchers meticulously adjusted for numerous demographic, health, and socioeconomic factors, the possibility of residual confounding, often termed "healthy user bias," cannot be entirely eliminated. Individuals who elect to receive vaccinations may inherently engage in healthier behaviors overall, or have better access to healthcare, which could independently contribute to better health outcomes. However, the study’s sophisticated matching methodology and extensive adjustment for confounding variables significantly mitigate this concern, providing strong evidence for a genuine association.

Follow-up Duration: The analysis specifically tracked outcomes during the first year after vaccination. While this period yielded significant results, the long-term effects beyond one year remain to be fully elucidated by this particular study. However, the mention of a previous study suggesting benefits lasting up to eight years in generally healthy adults offers a promising indication that the protective effects may be durable.

Future Research: To further solidify these findings and explore the underlying mechanisms, several avenues for future research are warranted:

• Longer-term Follow-up Studies: Prospective studies with extended follow-up periods are needed to confirm the durability of the cardiovascular benefits beyond one year in ASCVD patients.
• Mechanistic Studies: Research delving deeper into the precise biological pathways through which shingles infection increases cardiovascular risk and how vaccination modulates these pathways (e.g., specific inflammatory markers, vascular endothelial function, platelet activity) would provide invaluable insights.
• Randomized Controlled Trials (RCTs): While challenging and potentially unethical for vaccine studies if an effective vaccine is already available and recommended, an RCT specifically designed to assess cardiovascular endpoints could provide the highest level of evidence, if deemed feasible.
• Cost-Effectiveness Analysis: A detailed analysis of the cost-effectiveness of shingles vaccination when considering its cardiovascular benefits would be beneficial for healthcare policymakers.
• Diversity in Populations: Further studies in diverse global populations could confirm the generalizability of these findings.

Conclusion

The research presented at ACC.26 offers a compelling new dimension to the utility of the shingles vaccine. For millions of individuals living with atherosclerotic heart disease, the vaccine appears to be far more than just a shield against a painful rash; it emerges as a significant cardioprotective intervention, capable of nearly halving the rate of serious heart-related events and drastically reducing all-cause mortality within a year.

As medical science continues to uncover the intricate connections between seemingly disparate health conditions, the shingles vaccine stands out as a powerful example of how a targeted immunization can yield broad, life-saving benefits. These findings reinforce the critical importance of vaccination as a cornerstone of preventive medicine and provide a robust, evidence-based reason for healthcare providers, particularly cardiologists, to proactively recommend shingles vaccination to their high-risk patients, fostering healthier hearts and longer lives.